Viatris’ share price opened nearly 10% lower as the recently-formed generics and biosimilars giant announced weaker than anticipated financial guidance for 2021, with one analyst declaring that the figures “highlight the rapid and difficult underlying deterioration” in both Mylan and the Upjohn mature brands and off-patent business.
Financial guidance for this year includes estimated revenues of $17.2bn-$17.8bn and a net loss of $100m-$300m on a GAAP basis;...







